|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
FR2459619B1
(fr)
|
1979-06-26 |
1983-07-29 |
Agronomique Inst Nat Rech |
Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
|
|
US4350156A
(en)
|
1980-05-29 |
1982-09-21 |
Japan Foundation For Artificial Organs |
Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
|
|
US4455256A
(en)
|
1981-05-05 |
1984-06-19 |
The Regents Of The University Of California |
Bone morphogenetic protein
|
|
EP0693946B1
(en)
|
1993-03-24 |
2001-05-16 |
Owen Mumford Limited |
Improvements relating to injection devices
|
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
US5631347A
(en)
|
1995-06-07 |
1997-05-20 |
Eli Lilly And Company |
Reducing gelation of a fatty acid-acylated protein
|
|
DE19543737A1
(de)
|
1995-11-24 |
1997-05-28 |
Hoechst Ag |
Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
CA2337688C
(en)
|
1998-07-23 |
2016-04-05 |
Yeda Research And Development Co., Ltd. |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
PT2090583E
(pt)
|
1998-09-25 |
2011-09-14 |
Yeda Res & Dev |
Polipéptidos relacionados com o copolímero 1 para utilização a título de marcadores de massas moleculares e em terapêutica
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
WO2000027417A1
(en)
|
1998-11-12 |
2000-05-18 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
|
|
EP1261361B1
(en)
|
2000-02-18 |
2006-06-14 |
Yeda Research And Development Company, Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate)
|
|
ZA200206457B
(en)
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
PL363431A1
(en)
|
2000-06-05 |
2004-11-15 |
Teva Pharmaceuticals Industries, Ltd. |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
DE10158009A1
(de)
*
|
2001-11-21 |
2003-05-28 |
Begerow E Gmbh & Co |
Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen
|
|
EP1459065B1
(en)
|
2001-12-04 |
2010-07-28 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
US7777006B2
(en)
|
2002-12-31 |
2010-08-17 |
Csl Behring L.L.C. |
Method for purification of alpha-1-antitrypsin
|
|
RU2339397C2
(ru)
|
2003-01-21 |
2008-11-27 |
Йеда Рисерч Энд Дивелопмент Ко.Лтд. |
Сор1 для лечения воспалительных заболеваний кишечника
|
|
EP1603530A1
(en)
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
PL1638589T3
(pl)
|
2003-05-14 |
2014-10-31 |
Teva Pharmaceutical Industries Ltd |
Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego
|
|
RU2426590C2
(ru)
|
2003-07-18 |
2011-08-20 |
Бакстер Интернэшнл Инк. |
Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
|
|
WO2005041933A1
(en)
|
2003-10-31 |
2005-05-12 |
Teva Pharmaceutical Industries, Ltd. |
Nanoparticles for drug delivery
|
|
EP1701971A2
(en)
|
2003-12-31 |
2006-09-20 |
F.Hoffmann-La Roche Ag |
Peptide synthesis using decanting filter
|
|
US20070244056A1
(en)
|
2004-03-03 |
2007-10-18 |
Liat Hayardeny |
Combination Therapy With Glatiramer Acetate and Riluzole
|
|
US7655221B2
(en)
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US20090048181A1
(en)
|
2004-09-02 |
2009-02-19 |
Schipper Hyman M |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
HRP20160455T1
(hr)
|
2004-09-09 |
2016-07-15 |
Yeda Research And Development Co., Ltd. |
Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
|
|
CA2579656C
(en)
|
2004-09-09 |
2014-11-04 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparation of mixtures of polypeptides using purified hydrobromic acid
|
|
ATE440888T1
(de)
|
2004-10-29 |
2009-09-15 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
|
AU2006211510B8
(en)
|
2005-02-02 |
2011-04-21 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
RS52867B
(sr)
|
2005-02-17 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
|
|
EP1891233A4
(en)
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
|
US20070059798A1
(en)
|
2005-09-09 |
2007-03-15 |
Alexander Gad |
Polypeptides useful for molecular weight determinations
|
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US20080118553A1
(en)
|
2006-06-12 |
2008-05-22 |
Anton Frenkel |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
DE602007003848D1
(de)
|
2006-07-05 |
2010-01-28 |
Momenta Pharmaceuticals Inc |
Verbessertes verfahren zur herstellung von copolymer-1
|
|
CN100569282C
(zh)
|
2006-10-13 |
2009-12-16 |
俞嘉林 |
注射用骨肽冻干剂及其制备方法
|
|
AU2008265692A1
(en)
|
2007-06-21 |
2008-12-24 |
Momenta Pharmaceuticals, Inc. |
Copolymer assay
|
|
EP2173766A1
(en)
|
2007-07-31 |
2010-04-14 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
BRPI0819001A2
(pt)
|
2007-11-28 |
2014-10-07 |
Teva Pharma |
"método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
|
|
RU2469726C2
(ru)
|
2008-05-14 |
2012-12-20 |
Отономи, Инк. |
Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
|
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PT2275086E
(pt)
|
2009-07-15 |
2012-05-18 |
Teva Pharma |
Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
|
|
SI2405749T1
(sl)
|
2009-08-20 |
2013-10-30 |
Yeda Research And Development Co., Ltd. |
Nizkofrekventna terapija z glatiramer acetatom
|
|
ITMI20092069A1
(it)
|
2009-11-25 |
2011-05-26 |
Biofer Spa |
Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro.
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
PT2627669T
(pt)
|
2010-10-11 |
2016-11-24 |
Teva Pharma |
Biomarcadores de citocina como biomarcadores preditivos de resposta clínica para acetato de glatirâmero
|
|
WO2012123959A2
(en)
|
2011-02-14 |
2012-09-20 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
US8575198B1
(en)
*
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
MX2014004309A
(es)
|
2011-10-10 |
2015-07-06 |
Teva Pharma |
Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
|
|
EP3466964A1
(en)
*
|
2012-07-06 |
2019-04-10 |
3-D Matrix Ltd. |
Fill-finish process for peptide solutions
|
|
US9617596B2
(en)
|
2012-10-10 |
2017-04-11 |
Teva Pharmaceutical Industries, Ltd. |
Biomarkers predictive for clinical response for glatiramer acetate
|
|
MX2015008754A
(es)
|
2013-01-04 |
2016-04-11 |
Teva Pharma |
Caracterizacion de un medicamento relacionado con acetato de glatiramer.
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
CA2903127A1
(en)
|
2013-03-12 |
2014-10-09 |
Teva Pharmaceutical Industries Ltd. |
Rituximab induction therapy followed by glatiramer acetate therapy
|
|
CN103169670B
(zh)
*
|
2013-03-22 |
2016-07-06 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷微球及其制备方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|